Background CD4^＋T cell counts have been used as the indicator of human immunodeficiency virus type 1 （HIV-1） disease progression and thereby to determine when to start highly active antiretroviral therapy （HAART）...Background CD4^＋T cell counts have been used as the indicator of human immunodeficiency virus type 1 （HIV-1） disease progression and thereby to determine when to start highly active antiretroviral therapy （HAART）. Whether and how the baseline CD4^＋T cell count affects the immunological and viral responses or adverse reactions to nevirapine （NVP）-containing HAART in Chinese HIV-1 infected adults remain to be characterized. Methods One hundred and ninety-eight HIV-seropositive antiretroviral therapy （ART）-naive subjects were enrolled into a prospective study from 2005 to 2007. Data were analyzed by groups based on baseline CD4^＋T cell counts either between 100-200 cells/μl or 201-350 cells/μl. Viral responses, immunologic responses and adverse events were monitored at baseline and at weeks 4, 12, 24, 36, 52, 68, 84, 100. Results Eighty-six and 112 subjects ranged their CD4^＋T cell counts 100-200 cells/μl and 201-350 cells/μl, respectively. The pre-HAART viral load in CD4 201-350 cells/μl group was significantly lower than that in CD4 100-200 cells/μl group （P=0.000）. After treatment, no significant differences were observed between these two groups either in the plasma viral load （pVL） or in the viral response rate calculated as the percentage of pVL less than 50 copies/ml or less than 400 copies/ml. The CD4^＋T cell counts were statistically higher in the 201-350 group during the entire follow-ups （P 〈0.01） though CD4^＋ T cell count increases were similar in these two groups. After 100-week treatment, the median of CD4^＋ T cell counts were increased to 331 cells/μl for CD4 100-200 cells/μl group and to 462 cells/μl for CD4 201-350 cells/μl group. Only a slightly higher incidence of nausea was observed in CD4 201-350 cells/μl group （P=0.05） among all adverse reactions, including rash and liver function abnormality. Conclusions The pVLs and viral response rates are unlikely to be associated with the baseline CD4^＋T cell counts. Initiating HAART in Chinese H展开更多
Background The incidence of HIV-1-related infection d iseases and the mortality of AIDS have dramatically decreased since highly activ e antiretroviral therapy began to be used clinically in China in 1999. And we in i...Background The incidence of HIV-1-related infection d iseases and the mortality of AIDS have dramatically decreased since highly activ e antiretroviral therapy began to be used clinically in China in 1999. And we in itiated a second clinical trial using a combination of Efavirenz and Indinavir to observe the effects of the immunoreaction.Methods Twenty patients with laboratory-confirmed chronic HIV-1 infection were recruited. Blood samples were collected initially and during the weeks after initiation of treatment. Within 48 hours of blood sampling, peripheral blood plasma and mononuclear cells were separated using routine methods. HIV-1 viral load was measured in thawed plasma samples. Within 48 hours of peripheral blood sampling, CD4 + and CD8 + T cell subsets were enumerated.Results The drug regimen was efficient in reducing HIV-1 plasma viral load and increasing total CD4 + T cell counts. The percentage of CD4 + and CD8 + T cel l subsets expressing CD38 and HLA-DR activation markers was positively correlated with plasma viral load and tended to normalize.Conclusions The combination of Efavirenz and Indinavir was generally well tolerated and efficient at reducing HIV-1 RNA. Furthermore, the treatment improved the immunological function.展开更多
文摘目的探究干扰素诱导蛋白-10(interferon-inducible protein-10,IP-10)、IL-37、半胱氨酸蛋白酶-1(caspase-1,Casp-1)在AIDS患者中的表达情况及其与临床特征的相关性。方法选取2019年2月—2020年2月我院收治的59例AIDS患者为观察组,同期59例健康志愿者作为对照组,其中观察组给予高效抗反转录病毒治疗(high active anti-retroviral therapy,HAART)12个月。采用酶联免疫吸附试验检测观察组治疗前后及对照组血清中IP-10、IL-37、Casp-1水平,采用流式细胞仪检测观察组治疗前后血液中CD4^(+)T细胞水平,采用HIV-1载量检测仪检测观察组治疗前后血浆中HIV-1载量。结果与对照组相比,观察组治疗前血清IP-10、Casp-1水平较高,IL-37水平较低(P均<0.05)。与经性传播、无生殖器疱疹、无淋巴瘤患者相比,经血液传播、有生殖器疱疹及淋巴瘤患者血清中IP-10、Casp-1水平较高,IL-37水平较低(P均<0.05)。观察组治疗后IP-10、Casp-1、HIV-1载量下降,IL-37、CD4^(+)T细胞水平升高(P均<0.05)。IP-10与CD4^(+)T细胞水平呈负相关(r=-0.481,P<0.05),IL-37与CD4^(+)T细胞水平呈正相关(r=0.534,P<0.05),Casp-1与CD4^(+)T细胞水平呈负相关(r=-0.392,P<0.05)。结论AIDS患者IP-10、Casp-1水平表达异常升高,IL-37水平异常降低,可辅助CD4^(+)T细胞诊断AIDS,并作为预后标志物,用于监测AIDS患者的疾病进展和HAART的效果。
文摘Background CD4^＋T cell counts have been used as the indicator of human immunodeficiency virus type 1 （HIV-1） disease progression and thereby to determine when to start highly active antiretroviral therapy （HAART）. Whether and how the baseline CD4^＋T cell count affects the immunological and viral responses or adverse reactions to nevirapine （NVP）-containing HAART in Chinese HIV-1 infected adults remain to be characterized. Methods One hundred and ninety-eight HIV-seropositive antiretroviral therapy （ART）-naive subjects were enrolled into a prospective study from 2005 to 2007. Data were analyzed by groups based on baseline CD4^＋T cell counts either between 100-200 cells/μl or 201-350 cells/μl. Viral responses, immunologic responses and adverse events were monitored at baseline and at weeks 4, 12, 24, 36, 52, 68, 84, 100. Results Eighty-six and 112 subjects ranged their CD4^＋T cell counts 100-200 cells/μl and 201-350 cells/μl, respectively. The pre-HAART viral load in CD4 201-350 cells/μl group was significantly lower than that in CD4 100-200 cells/μl group （P=0.000）. After treatment, no significant differences were observed between these two groups either in the plasma viral load （pVL） or in the viral response rate calculated as the percentage of pVL less than 50 copies/ml or less than 400 copies/ml. The CD4^＋T cell counts were statistically higher in the 201-350 group during the entire follow-ups （P 〈0.01） though CD4^＋ T cell count increases were similar in these two groups. After 100-week treatment, the median of CD4^＋ T cell counts were increased to 331 cells/μl for CD4 100-200 cells/μl group and to 462 cells/μl for CD4 201-350 cells/μl group. Only a slightly higher incidence of nausea was observed in CD4 201-350 cells/μl group （P=0.05） among all adverse reactions, including rash and liver function abnormality. Conclusions The pVLs and viral response rates are unlikely to be associated with the baseline CD4^＋T cell counts. Initiating HAART in Chinese H
文摘Background The incidence of HIV-1-related infection d iseases and the mortality of AIDS have dramatically decreased since highly activ e antiretroviral therapy began to be used clinically in China in 1999. And we in itiated a second clinical trial using a combination of Efavirenz and Indinavir to observe the effects of the immunoreaction.Methods Twenty patients with laboratory-confirmed chronic HIV-1 infection were recruited. Blood samples were collected initially and during the weeks after initiation of treatment. Within 48 hours of blood sampling, peripheral blood plasma and mononuclear cells were separated using routine methods. HIV-1 viral load was measured in thawed plasma samples. Within 48 hours of peripheral blood sampling, CD4 + and CD8 + T cell subsets were enumerated.Results The drug regimen was efficient in reducing HIV-1 plasma viral load and increasing total CD4 + T cell counts. The percentage of CD4 + and CD8 + T cel l subsets expressing CD38 and HLA-DR activation markers was positively correlated with plasma viral load and tended to normalize.Conclusions The combination of Efavirenz and Indinavir was generally well tolerated and efficient at reducing HIV-1 RNA. Furthermore, the treatment improved the immunological function.
